Despite their demonstrated efficacy in melanoma, lung cancer, lymphoma, and hepatocellular carcinoma (110), PD-1/PD-L1 checkpoint inhibitors continue to show limited effectiveness in PCa. The gene discussed is CD274; the disease is lymphoma.